VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
CanSino Biologics: 24-Valent Pneumococcal Conjugate Vaccine Enters Phase I/II Clinical Trial with First Subject Enrolled
CanSino Biologics: 24-Valent Pneumococcal Conjugate Vaccine Enters Phase I/II Clinical Trial with First Subject Enrolled
May 25, 2026 16:14 CST Updated 16:37
Share:
